TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: symptomatic pseudarthrosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tumor responses (complete and partial responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Persistence of hyperthyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to elimination of hyperthyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average total cost of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Marked LDL reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Confirmed active tuberculosis
Endpoint domain: Mortality/survival
Primary endpoint: Treatment completion rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adverse events of grade 3 to 5
Endpoint domain: Adverse events/effects
Primary endpoint: IOP change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subclinical respiratory depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall of some part of the procedure
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: relapse frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone collagen maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rates (UCSS < or =2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of swallows needed to clear the esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of triggered secondary contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Latency between air injection and onset of secondary peristalsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Annual rate of symptomatic ASD
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal Mouth Opening (MM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical Dimension of Occlusion (VDO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: atrial contraction synchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: global cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: One-legged hopping movement pattern stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of not optimal SCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemical composition changes in enamel and dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of cannula replacements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Unplanned removals of cannulas
Endpoint domain: Adverse events/effects
Primary endpoint: Re-siting of peripheral venous cannulas
Endpoint domain: Adverse events/effects
Primary endpoint: average low-density lipoprotein (LDL) particle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak low-density lipoprotein (LDL) particle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Remission of eating disorder diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: CIS-fatigue score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Increase in Faecalibacterium prausnitzii populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Bacillus spp. populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle oxidative capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycolytic enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skeletal muscle integrity and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: physical health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-efficacy beliefs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: risk for stronger pain (NRS>3) on the third postoperative day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean transmission risk acts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: vasoplegic syndrome incidence
Endpoint domain: Adverse events/effects
Primary endpoint: average intensive care unit stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Increase in ventilator-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle change of miniscrews
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perceived ability to cope with other symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Control of BP (BP < 140/90 mm Hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Freezing of Gait (FOG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year cardiac mortality in subjects with LVEF<50%
Endpoint domain: Mortality/survival
Primary endpoint: improvements in LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: one extra life year saved
Endpoint domain: Mortality/survival
Primary endpoint: Clinical severity score of AD (SCORAD value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV end diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV end systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sphericity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anterior chamber depth change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central corneal thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central corneal refraction change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemoglobin drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: subcutaneous abdominal adipose tissue blood flow (ATBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adipose tissue TAG clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS‐QoL improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gut-specific anxiety improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean improvement scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from time 0 to 480 minutes (AUC(0‐480))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum observed drug concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in patient-assessed pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in patient-assessed significant pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for falling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores on a visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of AF recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in PTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Repigmentation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of pathological ECG changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Family accommodation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: muscle quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quadriceps cross‐sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep onset latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Persistent sleep latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Severity of erythema at 60 min after patch removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of erythema at 72 h after patch removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of topical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of responders at 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dropouts due to seizure recurrence or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Invasive Fungal Infection (IFI)
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality related to Invasive Fungal Infection (IFI)
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in CAL (Clinical Attachment Level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in GCF (Gingival Crevicular Fluid)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion with normal functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: pain experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: minor side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Optimal positioning for femoral IMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: T2T implementation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FA values of total corpus callosum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MD values of total corpus callosum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AD values of total corpus callosum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primary efficacy event rate
Endpoint domain: Mortality/survival
Primary endpoint: primary safety event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Left atrium dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: P-duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lumbar spine BMD changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hip BMD changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone turnover markers (D-Pyr, alkaline phosphatase, osteocalcin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean MoCA scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intentions to use e-cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive attitudes toward e-cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement of endoscopic skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative mydriasis using 5% phenylephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative blood pressure stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ulcer healing at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median ulcer-free time during the first year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comprehensive curative effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficacy on membranous lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improving tenesmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: antileukemic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inner diameter and blood flow of arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Yearly progression rate of JSW change of hand and wrist joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: JSN of the hand and wrist according to SHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 24-hour urine leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time after lens removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 1RM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ART initiation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical trauma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: surgical exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to first recurrence of genital herpes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients remaining free of HSV recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global physician assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatigue severity score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: serum MDA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glutathione reductase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Termination of SVT episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Termination of VT episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of the algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Natural killer (NK) cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophil iodination activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymphotoxin production by lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Parental restriction of high-risk teen driving conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with clinically significant improvement of blood glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: remineralization ratio values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in tracking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall survival rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Relative abundance of Faecalibacterium, Clostridium, Dialister, and Roseburia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fecal secondary bile acids (deoxycholic acid and lithocholic acid)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: WHO classification improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infusion site pain
Endpoint domain: Adverse events/effects
Primary endpoint: CD4 cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in pain during chemical peeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mesh exposure
Endpoint domain: Adverse events/effects
Primary endpoint: Bone augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: documentation audit scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective rate of Yinhua mixture aerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective rate of gentamycin aerosol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Association of AS scores with muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Association of AS scores with resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intraclass correlation coefficient for absolute agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal pathologic response (OPT) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete erection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pharyngolaryngeal complications
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in dephosphorylated-uncarboxylated MGP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED documentation of cases of possible physical child abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: migration (MTPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional obstacle course quality improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional obstacle course completion time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occlusal wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: marginal integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of failure
Endpoint domain: Adverse events/effects
Primary endpoint: Median MED increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cutaneous blood flow change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: VAS activity pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS night pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain-free grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deficits in working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Deficits in executive function (verbal fluency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes